Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
Future Oncology | January 31, 2026 | Volume: 22 | Issue: 3 | Pages: 339-348
10.1080/14796694.2026.2615736
| PMID 41618895